Linda Duska - Concepedia

Author

Linda Duska

University of Virginia ORCID

Also Known As

Adil Daud, Duska, Linda R, Hay, Casey M., L Duska, L R Duska, L. Duska, L. R. Duska, L.R Duska, L.R. DUSKA, L.R. Duska

456

Publications

7.9K

Citations

H-Index

121

Concepts

All Affiliations

University of Virginia Massachusetts General Hospital Dana-Farber Cancer Institute University of Virginia Health System Brigham and Women's Hospital

About

Linda Duska is an author at University of Virginia specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	80	3.8K
2	Public Health	11	11	449
3	Health Sciences	10	12	672
4	Nursing	7	7	184
5	Social Sciences	2	2	55

Linda Duska

123

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Robert E. Bristow, Linda Duska, Nicholas C Lambrou, Cancer	2000	323
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, New England Journal of Medicine	2023	316
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Journal for ImmunoTherapy of Cancer	2022	300
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Domenica Lorusso, Yang Xiang, Kosei Hasegawa, The Lancet Advanced Cervical CancerCervical CancerCervical HealthMedicineMetronomic Therapy	2024	296
Endometrial Cancer in Women 40 Years Old or Younger Linda Duska, Audrey P. Garrett, Bo R. Rueda, Gynecologic Oncology MedicineEndometriosisCarcinomaGynecologyMenopause	2001	238
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, The Lancet Oncology MedicineGemcitabine Versus GemcitabineMetronomic TherapyGynecologyCancer Treatment	2020	227
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel Richard T. Penson, K. Kronish, Zhenfeng Duan, International Journal of Gynecological Cancer	2000	194
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, The Lancet OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer	2023	175
Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences Robert A. Soslow, John P. Bissonnette, Andrew S. Wilton, The American Journal of Surgical Pathology	2007	166
Frailty: An outcome predictor for elderly gynecologic oncology patients Madeleine Courtney‐Brooks, A. Rauda Tellawi, Jennifer Scalici, Gynecologic Oncology Geriatric OncologyAgingGeriatricsLongevityGynecology	2012	137

Page 1